Spectris plc

Good morning, everyone. I'm Andrew Heath, Chief Executive of Spectrus, and with me today is Angela Noon, our Chief Financial Officer. Thank you for joining us on this webcast as we present our results for the first half of 2025. We entered 2025 expecting a recovery in a number of our end markets. Clearly, the macroeconomic backdrop has been more challenging than we expected coming into the year. and the uncertainty caused by tariffs has led to continued customer caution. However, we have demonstrated the resilience of the group and delivered a robust first half performance. The improved momentum seen in the second quarter, particularly in Spectra Scientific, is encouraging and provides us with confidence in the outlook for the rest of 2025 and going into 2026. And I'll come back to this on the next slide. So starting with sales, reported revenue was 8% higher in the first half, including 20% growth in the second quarter, recovering the dip that we saw in Q1. While we did have a softer year-on-year comparator in Q2, nonetheless, after a prolonged and largely unprecedented downturn, we are now seeing building momentum in our end market-driven demand. Reported order intake was 5% higher in the first half, including 15% growth in the second quarter, with a book-to-bill ratio of just over one. That led to adjusted operating profit of £65.6 million, which was up 3% on a reported basis. Cash generation and returning leverage back within our one to two times target range remains a key focus for the group. We delivered a very strong cash performance in the first half, with cash conversion of 126%. And we've declared an interim dividend of 28 pence per share, which represents 5% growth on the 2024 interim dividend. Our profit improvement programme remains firmly on track to deliver at least £30 million of savings this year. Over £10 million was delivered in the first half, with more than £20 million expected to be realised in the second half. Cost synergies have already started to come through. We are seeing the benefits of the new ERP system in mobile and political and HPK, and headcount has been right-sized for current demand levels. Turning to last year's acquisitions, I'm delighted with the integration progress that has been made in the first half, In Malvern Panelistical, we have made great progress in successfully integrating micromeretics and SIAPS, including implementing a new organizational structure and reworked sales model. SIAPS is our new center of excellence for handheld instruments, which incorporates Malvern Panelistical's existing handheld business. And we are already seeing the benefits of collaboration between these two businesses, both in terms of accelerated sales and new products. In Dynamics, again, PiezoCRIST has been integrated into HBK. The PiezoCRIST and DITRAN teams are already working on developing a new groundbreaking high temperature accelerometer for demanding applications. And there are lots more new products in the pipeline. Through the integration process, it has become increasingly clear that the synergy opportunities are greater than those that we outlined in the acquisition business case. There is greater scope for cost synergies, which is a key driver for our upgraded cost savings target, and early discussions with customers have given us confidence in respect to greater potential revenue synergies as well. And finally, I just wanted to provide a summary of where we are regarding the prospective takeover of the group. As you know, on the 23rd of June 2025, the Board announced that they had reached agreement on the terms of a recommended cash acquisition by Advent for the entire issued and to be issued share capital of Spectrus for an offer value of £37.63 per Spectrus share, comprising £37.35 in cash. and an interim dividend of 28 pence per spectre share, and that's to be implemented by way of a court-sanctioned scheme of arrangement under Part 26 of the Companies Act. Subsequently, we recommended an offer from KKR at £40 per share on 2 July, followed by an improved offer from Advent last Friday at £41. The board then switched its recommendation again on the 5th of August, following an offer of £41.75 per Spectra share from KKR, which again includes an interim dividend of 28 pence per share. This represents a 104.9% premium to the undisturbed share price on the 6th of June and equates to a 20.3 times 2024 adjusted EBITDA for the Spectras Group. So in terms of the timeline from here, pending the acceptance of the offer from shareholders, completion is currently estimated in or by the first quarter of 2026, once regulatory approvals have been granted. This next slide provides some more color on what we are seeing in our end markets and also the signs of recovery that are emerging. One of the key indicators we look at internally is the momentum in our quarterly growth rate compared to that in our annual growth rate. When quarterly growth crosses above the annual growth line, this is often a good predictor of recovery. As you can see in the chart on the left-hand side, both orders and sales, the indicator suggests we have been in the early stages of recovery for the past 12 months. Orders have been in accelerating growth territory for the past eight to 10 months on a like-for-like and reported basis, and also moving to positive growth from quarter four. Clearly, the macroeconomic environment is still challenging. We continue to expect to broadly mitigate the direct impact of tariffs, but at the same time, we're also mindful of significant uncertainty still remaining. It's too early to call a sustained recovery, but this does provide us of the year. Orders at the end of the first half were up on the prior year, with the exception of automotive, clean tech and aerospace events, which had a very tough comparator. Automotive was down double digits, as larger CapEx and R&D projects are being delayed by customers due to the ongoing tariff and macro uncertainty. The table on the right-hand side shows the like-for-like sales performance by in-market for both the first half and the second quarter. The first thing to note is the significant improvement in sales growth in the second quarter at the group level. Now, having been down 8% in the first quarter, on a like-for-like basis, we grew by 9% in the second quarter. Part of this is clearly due to the softer year-on-year comparator that we had in Spectra Scientific, but we are seeing improving momentum in a number of our end markets, where we saw a notable increase in sales growth in Q2. Materials, academia and life sciences delivered the strongest growth, and it was also pleased to see pharma getting back to growth by the end of the period. Now, one quarter doesn't make a trend, so we're not getting carried away, but it's pleasing to see the improving momentum is broad-based across most of our end markets. And with that, I'll hand over to Angela to take you through the financials.

Thank you, Andrew, and good morning, everyone. I'm delighted to be here this morning to run through our H1 financial results. Let's jump straight into the numbers. I'll start with some of the key highlights for the first half of 2025. Orders were 2% lower on a like-for-like basis. As you heard from Andrew, we saw improved momentum throughout the periods, such that our like-for-like order intake in the second quarter was up by 4%. Our book-to-bill ratio was just over one times in the period. Sales were 1% higher on a like-for-like basis, with a very strong second quarter where sales grew 9% like-for-like, albeit helped by an easier comparator in Spectra Scientific. And of course, our reported numbers were even stronger due to the acquisitions made in 2024. Profit largely followed the sales performance with flat growth on like-for-like basis equating to an adjusted operating margin of 10.3%. Moving on to cash, I'm very pleased with the first half cash performance of the group. Adjusted cash flow was a very strong £82.4 million, resulting in cash conversion of 126%, which is the highest in many years outside of COVID. This was driven by a strong working capital performance in the period, mainly from the reduction in customer debt and improved management of creditors. There is scope for further working capital improvement, certainly in the second half. Our return on gross capital employed fell to 12.2% as a result of the increase in debt associated with the acquisitions. Net debt overall stands at £546 million with leverage of 2.3 times on a covenant basis, both broadly unchanged from the end of 2024. Given the typical seasonality of our cash flow, this is a very strong cash performance and I would expect material reductions in net debt and leverage in the second half. The next table provides a bridge between adjusted and statutory operating profit, as well as profit before tax. Costs associated with our profit improvement programme totaled £12 million. I am pleased to confirm that the programme is moving at pace and is in line with plan. My expectation is that we should exceed our original savings target of £30 million by the end of the financial year. A credit of £16.8 million includes an £18.1 million fair value adjustment, which relates to the release of deferred consideration partially offset by related fees. Public offer related costs, which refers to takeover costs incurred by Spectris thus far, was 7.9 million in the first half. Software implementation costs were 13 million pounds down from 22 million pounds last year. We have now reached steady state in Malvern Panalytical and for the first phase of Dynamics. So our ERP project costs have reduced substantially. We expect to see improved cost effectiveness from here. Our recent acquisitions have led to an increase in amortisation to £24.7 million. As a result, statutory operating profit was £24.8 million, broadly the same as last year. Further down the table, I want to remind everyone of the £210 million gain that we had on the disposal of Red Lion last year. We also incurred £22.9 million of net interest costs in the period, which reflects the current net debt position of the group after the acquisition of Micromeretics, SciApps and Piazzo Christ. This next slide shows the main drivers of our sales and operating profit performance in the first half. The disposal of Red Lion in April 2024 meant that 20 million pounds of sales and 3.7 million pounds of operating profit that were reported in the first half of 24 did not reoccur in the first half of 25. We saw good operating leverage in the period, driven by strong contribution from price and pass-through of tariff to end customer. The increase in overheads is a net number, with savings from our profit improvement programme of approximately £10 million being offset by other items, including higher variable compensation year-on-year. foreign exchange was a headwind in the period due to the strength of sterling against the dollar the euro and the chinese renminbi as you can see our recent acquisitions have had the biggest impact on our p l performance in the first half while slightly softer than we anticipated we expect an improved profit contribution the second half of the year which i'll come back to later If we can now turn to cash and net debt. As said, I was very pleased with our first half cash performance, with our net debt unchanged, despite the payment of the final dividend. Our focus on working capital helped to deliver £15 million inflow in the first half, driven by receivables and payables. Our focus is now on further improvement in inventories, with detailed group reduction plans fully underway. We tend to build inventory in the second quarter ahead of our stronger second half, hence we expect larger working capital gains in the second half of the year. Capital expenditure, restructuring, ERP costs and interest costs were all in line with expectations and our full year guidance. We received a 1.9 million tax credit in the period as a result of rebates in the UK and Germany in particular. This was fully expected and we have left our full year cash tax guidance unchanged. The largest outflow was the 2024 final dividend that was paid out in June, whilst a foreign exchange translation inflow of £26.2 million reflects sterling strength against the US dollar and to a lesser extent the euro. Taking these movements all together, we finished the period with net debt of £546 million. As said again, largely unchanged compared to the financial year past. Coming on now to our divisional performance, starting with Spectra Scientific. Orders in the first half were 2% higher on a like-for-like basis compared with 14% growth in the second quarter. On a reported basis, orders grew by 17% in the first half and 32% in the second quarter. The book to bill ratio was 1.04. As the chart in the bottom right shows, like for like order growth has been positive in three of our last four quarters. And this building momentum is encouraging as we look ahead to the second half of this year and on to 2026. Sales in Spectra Scientific were 3% higher on a like-for-like basis, again driven by a strong second quarter, where like-for-like sales grew by 19%. This was due in part to an easier comparator. On a reported basis, sales were 21% higher in the first half, with 38% growth in the second quarter. Adjusted operating margin increased by 70 bps to 11.1%, driven by operating leverage and cost savings. Turning now to Spectris Dynamics, order intake in the first half was 7% lower on a like-for-like basis, driven by continued weakness in automotive. This was compounded by a tough comparator as we booked a number of large simulator orders in virtual tests last year. On a reported basis, orders were 3% lower in the first half. Book to Bill was slightly below one. You can see the impact of the automotive downturn in the order chart in the bottom right. Encouragingly, after a prolonged downturn, we continue to see good momentum in machine manufacturing, with aerospace and defence remaining robust. Sales and Spectra's dynamics were 3% lower on a like-for-like basis, again impacted by automotive weakness. On a reported basis, sales were flat to the first half. Adjusted operating margin was resilient, increasing by 10 bps to 12.4% despite lower sales volumes due to a very strong execution on cost savings. This next slide shows the three key profit drivers in the second half that give us confidence in meeting our full year expectations. Firstly, our profit improvement programme. In our April trading update, we communicated that we saw potential upside to our original cost savings target of £30 million for 2025. We can now confidently say that we expect to realise savings of over £30 million this year. With over £10 million of savings in the first half, we will also expect to deliver at least £20 million of savings in the second half. The programme was always expected to be second half weighted and potentially even more so given the upgraded cost saving target. Another driver of profit growth in the second half will be the contribution from the three acquisitions we made last year. Their profit contribution in the first half was slightly lower than we had expected, largely due to timing and delays due to export control as a result of tariff regimes. These orders will be delivered in the second half. In addition, the order intake in the three acquisitions has been strong in the first half, particularly SIAPS, which has seen order growth of over 30%. Their combined order backlog gives us confidence in their second half profit contribution, which we now expect to total approximately £20 million. This is a greater second half weighting than we originally anticipated. And then finally, as Andrew highlighted earlier, we are building momentum in the business, particularly in Spectra Scientific. Our Q2 performance, even allowing for the easier comparator, was encouraging. And whilst we are mindful that macroeconomic uncertainty stemming from tariffs remains elevated, the underlying organic improvement that we are seeing gives an element of confidence for the second half. But to be clear, we are not relying on a strong recovery in the second half to meet our expectations. Our profit improvement programme and the contribution from the acquisitions will be the most significant drivers of profit growth in the second half. And with that, I'd like to hand back to Andrew.

Thank you, Angela. Over the past seven years, we have repositioned Spectrus as a leader in precision measurement that have made great strides in advancing our purpose-led strategy, enabling our customers to make the world cleaner, healthier, and more productive. We have simplified and refocused the group through eight divestments and attractive valuations, redeploying the cash into 16 complementary acquisitions. We've also delivered strong capital returns to shareholders, with over one billion pounds returned through dividends and share buybacks alone. Through careful portfolio management, disciplined execution and strategy, and exceptional people, Spectrus has become a more focused, higher quality, and higher performing company. Our commitment to innovation, sustainability, and customer-centric solutions, compounded by our acquisitions, has positioned us as a leader in our markets. We have built a business geared for long-term growth in exciting, structurally growing end markets. The company's commitment to operational excellence and sustainability is not only improving margins, it is also enhancing our brand and position with customers, as well as creating a positive and lasting impact to the planet and society. During the global pandemic, we took the decision to establish the Spectrus Foundation to support and empower the next generation of innovators, particularly in underrepresented groups. To date, we've improved access to a high quality STEM education for over 50,000 students. And I'm pleased to say the foundation's impact continues to grow year on year. I am very proud of the transformation of the group since 2018. From the beginning, We have sought to create an environment where great talent can thrive in a healthy high performance culture, aligned behind a clear strategy and encouraged to aim high in our delivery. Thanks to the continued hard work of all my colleagues, Spectra today is a high quality business, well positioned for sustained success. So in summary, it is pleasing to see the clear momentum coming through in our first half results. We have delivered a robust first half performance in a tough economic environment. Encouragingly, momentum improved through the period with a very strong second quarter, particularly in Spectra Scientific. And we delivered strong cash conversion in the first half, underlining the group's highly cash-generative nature and our focus on deleveraging. Looking ahead to the rest of 2025, We now expect over £30 million of savings from our profit improvement programme for the full year, with most of that still to come in the second half. We anticipate a strong second-half performance from last year's acquisitions, with higher levels of synergies than our business case. We do see signs of recovery in many of our end markets, and while tariff-related uncertainty still remains, our second quarter performance was encouraging. And as ever, positive operating leverage will always help support our second half profit performance. With continued focus on working capital improvement, we expect to deliver another strong cash performance in the second half, providing confidence in bringing leverage back down within our one to two times target range by year end. And finally, turning to our guidance, we continue to expect adjusted operating profit to be in line with management expectations. With that, thank you for listening. Angela and I will be very happy to take your questions whilst recognizing that we are still in an offer period. And as such, when it comes to the prospective takeover of Spectrus, we can only comment on what is already in the public domain.

We will now begin the question and answer session. If you would like to ask a question, please press star followed by one on your telephone keypad. If for any reason you would like to remove that question, please press star followed by two. Again, to ask a question, press star one. If you're streaming today's call, please dial in and enter star one. As a reminder, if you're using a speakerphone, please remember to pick up your handset before asking questions. We will pause here briefly as questions are registered. The first question is from the line of Mark Davis Jones from Skippo. You may proceed.

Thank you very much. In the circumstances, Andrew, I think probably we can just ask you about some of the end markets trends you're seeing, particularly the life science pharmaceuticals, which is obviously very important for you. The commentary is still relatively muted, but the Q2 is very big. I know it's partly the comps, but are you seeing any willingness to invest back into instrumentation or is this other parts of that broader segment that is picking up? And Likewise, academia was, I guess, surprisingly strong given what's going on in the US. So could you comment on that too?

Of course, Mark. Thanks for your question. So, yes, I mean, it's great to see pharma getting back into growth in the first half of this year, you know, after what's been a really prolonged sort of depressed market. We've seen, you know, really pharma improve across Europe and Asia in particular. North America remaining relatively flat. But we are seeing an increased demand for instruments starting to come through, which is really pleasing. And I think if you compare that to some of our peers, there's been similar commentary in the latest quarterly reporting, particularly from the American peers. And on the academia side, again, we had a very strong quarter on academia after a bit of a weaker Q1. But if you remember, we also saw a big order of uplift in Q4. So it's proving to be somewhat lumpy. I think that's really driven by some of the uncertainty that's been caused by government supports in various countries around the world and customers having to navigate that, deciding when they're going to place their orders. But again, we saw academia up strongly in Europe in the first half. In Asia, it was pretty flattish, down in China. But even in North America, we were in academia. So despite some of the withdrawal of support in North America, we are still seeing demand coming through. And I think a lot of that is from the fact that, you know, a lot of the academic research institutes in the US have really over the last decade or so, you know, recognise that they can't rely so much on US government support. I mean, that has been slowly diminishing over the years. It's been a bit of a more recently, but I think a lot of it is now funded through sources other than the US government.

Great, thank you. And if I can just check on one of the weaker markets, obviously automotive is very tricky, but are you still seeing decent demand for the virtual testing side of things? Because there's been some suggestion people are focusing more on that as a lower cost way of doing R&D.

Yeah, so it's a bit of a mixed picture. I mean, if I give you sort of just sort of a flavour, I mean, really, you know, we saw North America down in auto last year. You know, there's quite a correction in North America with the move away from sort of EV platforms, particularly in the US. And that, you know, so our sales and orders into, well, our orders into North America are actually flat year over year. That really is a consequence if the OEMs decided to cancel or change any of their platform programs, it then takes some time for the new innovations, new platforms to start to come through for us to then benefit from the orders associated with those. So North America, against an easier con, was flat in the first half, but we did see some China down, you know, because of, I think, a lot of that sort of more of the electric battery investment that was made through to sort of the end of 23. There's been less repeat orders on that side of things in China. But the big downturn is in Europe, particularly in Germany, where we are seeing quite a disruption amongst our OEM customers. And as a consequence of that, you know, that's not only leading to sort of over for our products and services, but it's also impacting some of the, particularly the larger sort of CapEx projects associated with virtual tests. Some of our large simulators, three, four million the cost to customers. So we are seeing some of those projects being delayed and customers just taking longer to take decisions. I think the positive side to it, though, is that we are still seeing a good pipeline of prospective orders. It's just taking us longer to convert those orders as customers are managing their CapEx budgets and keeping an eye on what's happening in the wider market.

Excellent. Thank you very much.

We do have another question in queue. We have a question from the line of Bruno Johnny with UBS. You may proceed.

Thank you for taking my questions. The first one is just on the medium to long-term outlook for the group. I appreciate there's uncertainty in the market today, but if we take a step back, how do you think about the three to five-year outlook for Spectras? Have the drivers changed all that much compared to the CMD three years ago? Has something changed in terms of how you structurally view the market in light of recent policy uncertainty? Or perhaps are you just as confident or perhaps even more confident given recent acquisitions in terms of the group's growth and margin potential in the medium term? Just some thoughts there would be interesting.

Yeah, Bruno, nice to hear from you again, and thanks for your question. Look, I think the strategy that we laid out in October of 22 at our last Capital Market Day absolutely remains in place. I think if you, you know, sort of reflection since then, we've been through quite an almost unprecedented period of not just sort of prolonged weakness in end markets, but also, you know, we'd really seen, you know, we saw weakness really across nearly all unusual for us. I would say that, you know, given what I said in the presentation earlier, and just looking at our sort of growth rates over the last 12 months, you can see that we've been in accelerating growth since the middle of last year, and then crossed into positive growth in Q4. And that's the same story, whether you look at it on a reported basis or graphs look very similar. So I'm very confident in the strategy that we laid out that we are an attractive long term sustainable growth markets. And I'm still very bullish about the future for the group based on the fact that we have been executing a consistent strategy. We've been investing in very much sort of customer backed innovation. We have elevated our R&D levels. improving and innovation is really key for driving future demand for the group. So I remain both confident in our end markets that they have got very good structural drivers and given our strategy has been to very much target those structural drivers in our end markets where we have leading positions with our technology and where we're innovating to create leading positions and we have a pretty strong moat around those, the prospects for the group remain very positive.

That's very clear. I'm just interested in the Q2 book to bill. It appears that orders grew well year over year and quarter over quarter. However, book to bill was modestly below one. I suspected this was perhaps due to some customers pulling forward orders in light of tariff uncertainty, which explains the strong Q2 sales performance. So I guess I'm just wondering if you did see any pull forward in Q2 from Q3 or later quarters, and could you perhaps just discussed customer behavior and attitude in recent months and how they're navigating tariffs?

Yeah, so look, I think on the tariff situation, we continue to broadly pass on, pass through the tariff-related costs. I think customers are accepting of that and our peers are doing things, acting in a very similar manner. It has clearly caused some Q1, where customers were effectively waiting to see what was going to happen with the tariffs. And then over the last few months, as tariffs have swung in various jurisdictions or against various countries, we have had customers asking us to delay shipping product, which has sort of created some lumpiness. We're still seeing some of that. And certainly for some of the acquisitions, Mike Moretics has had some of that in Q2, where will get delivered in the second half now. So, you know, it's being disruptive, but I think the world, certainly as we're seeing it, you know, is sort of, I wouldn't say taking it in its stride necessarily, but it's accepting of it. And, you know, it's good to see that we are seeing the order momentum coming through in Q2. And as I said earlier, you know, the fact that we've been through this sort of quite unprecedented, prolonged and broad weakness in markets, We are seeing quite a lot of, I would say, pent-up demand from our customer base where our sales and order pipeline look really very positive. We have lots of opportunities to go after. It's just the time it takes to convert those orders continues to take longer than it has if you look at it on a historic basis. So I think there's certainly reasons for optimism there.

Understood. That's very clear. Could we just touch on the underlying profitability of the group in the first half and particularly scientific? Because last year you had a comparative that included a nasty impact from ERP, so circa around 15 million. So if we adjust for that, there's an underlying deterioration of around, I guess, 200 basis points on the group level and around 300 basis points in scientific, despite some modest organic sales growth and a strong contribution from cost savings. Could you perhaps maybe just elaborate a little bit in terms of whether there was something unusual that might have impacted underlying margin in H1. If it's just seasonality around acquisitions or contributions from acquisitions, that would be helpful.

Thanks for the question. There's nothing, there's no unusual impacts in H1 that have affected the margin quality at all. So probably just more the volume that that Andrew's just alluded to. We've had some delays in revenue as we exited Q2. I think looking forward, however, trying to get confidence around the profit margin in H2, there's a number of building blocks that I think we've touched on, which is, don't forget, we've not just got the acquisition we've also got sales synergies from the acquisitions that are on top within the scientific business and those are progressing at pace. We've already got identified sales synergies of between 10 and 15 million so we're actually exceeding the business plan and most of them are actually second half weighted We've touched on the Profit Improvement Programme itself has always been second half weighted and that is a full impact on profit margins. So the margin quality lifts up substantially. And then I'd say lastly, we've just got the general trend of the business where it's historically also always been 65 to 70% in the second half. We did have softness in some of our acquisitions in H1 and we expected revenue to be slightly higher. As Andrew said, some of that is export control topics related to tariffs. Those orders are sitting in the backlog and we're expecting those to execute in the second half as well. So again, contributing to the volume and ultimately the drop through on our operational gearing. And so, yeah, no, we're very confident in the path to the operating margin quality. That answers the question.

Follow on, sorry, Angela, in terms of you mentioned in the presentation, circa 20 million of incremental profit from those acquisitions in the second half, I guess. Or that might imply a margin north of 30 percent, but I'm not sure what we penciled in in terms of incremental sales. So could you perhaps either speak to the margin on that incremental profit contribution or, I guess, the absolute contribution from acquired sales or the incremental contribution from acquired sales in the second half?

I mean, it's a bit of a mixed bag, in all honesty. We've got a business like SciApps, who have got very, very high margins. There's a lot of software in the business. So they've got double-digit margin drop-through, but microberetic slightly less. So we haven't given colour on the breakdown of those three acquisitions. We always talk about them as a group. And I'd prefer not to get into the detail of it today. And I think the only thing you should take away is that we are exceeding the business plan and the margins themselves are performing as we expect.

Understood. Well, thank you very much. Both greatly appreciate the insights as always. Thank you.

All right.

Thank you.

There are no additional questions waiting at this time. I would like to pass the conference over back to the management team.

All right. Well, thank you, everyone, for joining. I appreciate, given our circumstance, relatively limited questions today. I understand that. But thank you for joining. Just by way of closing, I just want to sort of just emphasize some of the points I made earlier. I mean, really, since 2018, we've transformed the group into a portfolio of really high quality businesses with attractive growth and margin profiles that really positions the group for sustained success. Our expectations for this year are very much supported by our order momentum and an improving sales outlook, along with the expected benefits from the recent acquisitions and efficiency programmes that we've talked about. In the long term, our confidence in the group's continued success stems from our strategic investments, but also the strong execution track record that the group has demonstrated, as underpinned by exceptional people and a really healthy high-performance culture. Spectris is now extremely well-placed to harness the power of precision measurement in solving its very much for joining. I'm sure we'll speak soon.

Thank you.